Vancouver, British Columbia – May 13, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB) today announced it will present at the 2nd Annual Marcum MicroCap Conference at the Grand Hyatt in New York, NY on May 30, 2013.
Sirona Biochem’s Chief Executive Officer, Neil Belenkie will be the company’s presenter. The presentation will be webcast live and a link to the webcast will be made available and announced at a later date.
Presentation details as follows:
- Date and Time: 10:30am-11:00am EDT, May 30, 2013
- Venue: Grand Hyatt, New York, NY, Estate 6 Room
- Presenter: Neil Belenkie, Chief Executive Officer of Sirona Biochem
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
About the Marcum MicroCap Conference
The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization. The Conference is expected to draw more than 1,000 attendees including senior personnel from almost 100 presenting public companies. This invitation-only event attracts institutional investors including top fund managers and qualified high net worth investors, who focus on small cap equities.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.